BridgeBio Pharma, Inc. (BBIO) /
The profitability of BridgeBio Pharma, Inc. over the past 9 years
Chart BridgeBio Pharma, Inc.: gross profit, operating income, net income, fiscal 2017–2025 Open the chart →BridgeBio Pharma, Inc. reported a net loss of $724.93M in fiscal 2025, the latest fiscal year on file. That year it had gross profit of $481.11M and an operating loss of $523.41M. It reported a loss in all 9 years shown.
Year by year
| Fiscal year | Gross profit | Operating income | Net income |
|---|---|---|---|
| 2025ended Dec 31, 2025 | $481.11M* | -$523.41M | -$724.93M* |
| 2024ended Dec 31, 2024 | $218.02M* | -$592.97M | -$535.76M* |
| 2023ended Dec 31, 2023 | $6.86M* | -$607.37M | -$643.2M* |
| 2022ended Dec 31, 2022 | $74.21M* | -$512.2M | -$481.18M* |
| 2021ended Dec 31, 2021 | $66.98M* | -$576.63M | -$562.54M* |
| 2020ended Dec 31, 2020 | — | -$474.48M | -$448.72M* |
| 2019ended Dec 31, 2019 | — | -$266.24M | -$260.59M* |
| 2018ended Dec 31, 2018 | — | -$183.66M | -$130.75M* |
| 2017ended Dec 31, 2017 | — | -$43.86M | -$30.57M* |
Fiscal years as BridgeBio Pharma, Inc. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on BridgeBio Pharma, Inc.
- The revenue of BridgeBio Pharma, Inc.
- The cash flow of BridgeBio Pharma, Inc.
- The debt of BridgeBio Pharma, Inc.
- All of BridgeBio Pharma, Inc.'s financials, charted
Companies of a similar size
- TXTTextron Inc.
- ARCCAres Capital Corp
- LSCCLATTICE SEMICONDUCTOR CORP
- DOCHealthpeak Properties, Inc.
- MTZMASTEC INC
Not investment advice. This page shows what BridgeBio Pharma, Inc. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.